Because of its high prevalence, hypertension (HTN) will continue to exert an increased financial burden on both the individual and the governmental health budgets unless we consider changing our efforts in managing HTN. Since the discovery of the first antihypertensive agent, during the 19 century, we had been focusing on blood pressure (BP) treatment by lowering the systolic and diastolic levels. Over decades, multiple drugs and combinations were introduced to lower the BP and reduce target organ damage, but they were unsuccessful in reducing the incidence or significantly limiting the prevalence.
View Article and Find Full Text PDF